Management of papulopustular rosacea and perioral dermatitis with emphasis on iatrogenic causation or exacerbation of inflammatory facial dermatoses use of doxycycline-modified release 40mg capsule once daily in combination with properly selected skin care as an effective therapeutic approach

Journal of Clinical and Aesthetic Dermatology

Volumn 4, Issue 8, 2011, Pages 20-30

  Del Rosso, James Q ^a,b,c  

^a VALLEY HOSPITAL MEDICAL CENTER   (United States)

^b TOURO UNIVERSITY NEVADA   (United States)

^c Las Vegas Skin & Cancer Clinics Ltd   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BETAMETHASONE DIPROPIONATE; CETIRIZINE; CLOTRIMAZOLE; CORTICOSTEROID; DOXYCYCLINE; MOMETASONE FUROATE;

ACNE VULGARIS; ADULT; ALLERGIC RHINITIS; ARTICLE; ATOPIC DERMATITIS; CASE REPORT; CORTICOSTEROID INDUCED ROSACEA LIKE DERMATITIS; DISEASE ASSOCIATION; DRUG WITHDRAWAL; ECZEMA; ERYTHEMATOUS PEMPHIGUS; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPERLIPIDEMIA; MALE; PERIORAL DERMATITIS; ROSACEA; SEBORRHEIC DERMATITIS; SKIN CARE; SKIN DISEASE;

EID: 80755168037     PISSN: 19412789     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Warner MR, Camisa C. Topical corticosteroids. In: Wolverton SE, ed. Comprehensive Dermatologic Drug Therapy. 2nd ed. Philadelphia: Saunders-Elsevier; 2007:606-613.
2. Del Rosso JQ. Adult seborrheic dermatitis: a status report on practical topical management. J Clin Aesthet Dermatol. 2011;4(5):32-38.
3. Gollnick H, Cunliffe W, Berson D, et al. Management of acne: report from a global alliance to improve outcomes in acne. J Am Acad Dermatol. 2003;49(1):S1-S37. (Pubitemid 36791495)
4. Crawford GH, Pelle MT, James WD. Rosacea I: etiology, pathogenesis, and subtype classification. J Am Acad Dermatol. 2004;51:327-341. (Pubitemid 39178655)
5. Pelle MT, Crawford GH, James WD. Rosacea II: therapy. J Am Acad Dermatol. 2004;51:499-512.
6. Del Rosso JQ, Baum EW. Comprehensive medical management of rosacea: an interim study report and literature review. J Clin Aesthet Dermatol. 2008;1:20-25.
7. Del Rosso JQ, Baldwin H, Webster G. Rosacea medical management guidelines. J Drugs Dermatol. 2008;7:1-3.
8. Lipozencic J, Ljubojevic S. Perioral dermatitis. Clinics Dermatol. 2011;29:157-161.
9. Kanelleas A, Berth-Jones J. Perioral dermatitis. In: Lebwohl MG, Heymann WR, Berth-Jones J, Coulson I, eds. Treatment of Skin Diseases: Comprehensive Therapeutic Strategies. 3rd ed. Philadelphia: Saunders-Elsevier; 2010:547-548.
10. Chen AYY, Zirwas MJ. Steroid-induced rosacea-like dermatitis: case report and review of the literature. Cutis. 2009;83:198-204.
11. Gupta A. Perioral dermatitis. In: Williams H, Bigby M, Diepgen T, Herxheimer A, Nadir L, Rzany B, eds. Evidence-Based Dermatology. 2nd ed. Malden, Massachusetts: Blackwell Publishing; 2008:111-116.
12. Rappaport MJ, Lebwohl M. Corticosteroid addiction and withdrawal in the atopic: the red burning skin syndrome. Clinics Dermatol. 2003;21:201-214. (Pubitemid 36629332)
13. Rappaport MJ, Rappaport V. The red skin syndromes: corticosteroid addiction and withdrawal. Expert Rev Dermatol. 2006;1(4):547-561.
14. Dubus JC, Marguet C, Deschildre A, et al. Local side effects of inhaled corticosteroids in asthmatic children: influence of drug, dose, age, and device. Allergy. 2001;56:944-948. (Pubitemid 32835598)
15. Egan CA, Rallis TM, Meadows KP, et al. Rosacea induced by beclomethasone dipropionate nasal spray. Int J Dermatol. 1999;38:133-134. (Pubitemid 29136867)
16. Bhat YJ, Manzoor S, Qayoom S. Steroid-induced rosacea: a clinical study of 200 patients. Indian J Dermatol. 2011;56(1):30-32.
17. Weber G. Rosacea-like dermatitis: contraindication or intolerance reaction to strong steroids. Br J Dermatol. 1972;86:253-259.
18. Leyden JJ, Thew M, Kligman AM. Steroid rosacea. Arch Dermatol. 1974;110:619-622.
19. Sneddon I. Adverse effect of topical fluorinated corticosteroids in rosacea. Br Med J. 1969;1:671-673.
20. Guin JD. Complications of topical hydrocortisone. J Am Acad Dermatol. 1981;4:417-422. (Pubitemid 11094642)
21. Savin JA, Alexander S, Marks R. A rosacea-like eruption of children. Br J Dermatol. 1972;87:425-429.
22. Wilkin J, Dahl M, Detmar M, et al. Standard classification of rosacea: a report of the National Rosacea Society Expert Committee on classification and staging of rosacea. J Am Acad Dermatol. 2002;46:584-587.
23. Manders SM, Lucky AW. Perioral dermatitis in childhood. J Am Acad Dermatol. 1992;27:688-692.
24. Rappaport MJ, Rappaport V. Eyelid dermatitis to red face syndrome. J Am Acad Dermatol. 1999;41:435-442.
25. Hong SP, Oh Y, Jung M, et al. Topical calcitriol repairs epidermal permeability and antimicrobial barriers induced by corticosteroids. Br J Dermatol. 2010;162:1251-1260.
26. Kao JS, Fluhr JW, Man MQ, et al. Short-term glucocorticoid treatment compromises both permeability barrier homeostasis and stratum corneum integrity: inhibition of epidermal lipid syunthesis accounts for functional abnormalities. J Invest Dermatol. 2003;120:456-464. (Pubitemid 36298433)
27. Del Rosso J, Friedlander SF. Corticosteroids: options in the era of steroid-sparing therapy. J Am Acad Dermatol. 2005;53:850-858.
28. Sheu HM, Tai CL, Kuo KW, et al. Modulation of epidermal terminal differentiation in patients after long term cortico-steroids. J Dermatol. 1991;18:454-464.
29. Proksch E, Elias PM. Epidermal barrier in atopic dermatitis. In: Bieber T, Leung DYM, eds. Atopic Dermatitis. New York: Marcel Dekker; 2002:123-143.
30. Di Nardo A, Wetz PW. Atopic dermatitis. In: Leyden JJ, Rawlings AV, eds. Skin Moisturization. 1st ed. New York: Marcel Dekker; 2002:165-178.
31. McLean I. Loss-of-function mutations in the filaggrin gene lead to reduced level of natural moisturizing factor in the stratum corneum. J Invest Dermatol. 2008;128:2117-2119. (Pubitemid 352001213)
32. Dirschka T, Tronnier H, Folster-Holst R. Epithelial barrier function and atopic diathesis in rosacea and perioral dermatitis. Br J Dermatol. 2004;150:1136-1141. (Pubitemid 38932283)
33. Thiboutot D, Thieroff-Ekerdt R, Graupe K. Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: results of two vehicle-controlled, randomized phase III studies. J Am Acad Dermatol. 2003;48:836-845. (Pubitemid 36706214)
34. Elewski BE, Fleischer AB, Pariser DM. A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea. Arch Dermatol. 2003;139:1444-1450. (Pubitemid 37433134)
35. Torok HM. Rosacea skin care. Cutis. 2000;66(4 Suppl):14-16.
36. Jansen T, Melnick BC, Schadendorf D. Steroid-induced perioroficial dermatitis in children - clinical features and response to azelaic acid. Pediatr Dermatol. 2010;27:137-142.
37. Del Rosso JQ. Update on rosacea pathogenesis and correlation with medical therapeutic agents. Cutis. 2006;78:97-100. (Pubitemid 44433118)
38. Sapadin AN, Fleischmajer R. Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol. 2006;54:258-265. (Pubitemid 43144395)
39. Golub LM, Lee HM, Ryan ME, et al. Tetracyclines inhibit connective tissue breakdown by multiple nonantimicrobial mecahanisms. Adv Derm Res. 1998;12:12-26.
40. Webster G, Del Rosso JQ. Anti-inflammatory activity of tetracyclines. Dermatol Clin. 2007;25:122-135.
41. Del Rosso JQ. Anti-inflammatory dose doxycycline in the treatment of rosacea. J Drugs Dermatol. 2009;8:664-668.
42. Preshaw PM, Novak MJ, Mellonig J, et al. Modified-release subantimicrobial dose doxycycline enhances scaling and root planing in subjects with periodontal disease. J Periodontol. 2008;79:440-452.
43. Del Rosso JQ, Webster GF, Jackson M, et al. Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40 mg doxycycline, USP capsules) administered once daily for treatment of rosacea. J Am Acad Dermatol. 2007;56:791-802. (Pubitemid 46561002)
44. Subramanyan K. Role of mild cleansing in the management of patient skin. Dermatol Ther. 2004;17(suppl 1):26-34.
45. Del Rosso JQ. The use of moisturizers as an integral component of topical therapy for rosacea: clinical results based on the assessment of skin characteristics study. Cutis. 2009;84:72-76.
46. Del Rosso JQ, Schlessinger J, Werschler P. Comparison of anti-inflammatory dose doxycycline versus doxycycline 100mg in the treatment of rosacea. J Drugs Dermatol. 2008;7:1-4